2',3'-cGAMP Sodium Salt

別名：2'-3'-cyclic GMP-AMP Sodium, 2',3'-cGAMP Sodium

製品コード：S7904 純度：99.83%

2',3'-cGAMP Sodium Salt (2'-3'-cyclic GMP-AMP Sodium) is produced in response to DNA in the cytoplasm in mammalian cells and binds STING with high affinity and is an effective inducer of interferon-β (IFNβ). 2',3'-cGAMP binds to STING with Kd of 3.79 nM.

CAS No. 1441190-66-4 (free acid)

サイズ	価格(税別)	在庫状況
1mg	JPY 58500	国内在庫あり
5mg	JPY 149500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（1）

製品安全説明書

現在のバッチを見る：純度： 99.83%

99.83

2',3'-cGAMP Sodium Saltと併用されることが多い化合物

Canagliflozin (JNJ 28431754)

2',3'-cGAMP and canagliflozin combination is a novel therapy for osteosarcoma.

Wu W, et al. Cell Death Dis. 2022 Jun 3;13(6):523.

Vadimezan (DMXAA)

2',3'-cGAMP, and Vadimezan (DMXAA) are both capable of re-educating M2 cells towards an M1 phenotype.

Downey CM, et al. PLoS One. 2014 Jun 18;9(6):e99988.

BV-6

2',3'-cGAMP, and BV6 together exert antitumor effects on PC cells.

Hannes S, et al. Cell Death Dis. 2021 Aug 30;12(9):816.

3',3'-cGAMP

Both 2',3'-cGAMP and 3',3'-cGAMP equally mature human monocyte-derived DCs, upregulating CD40/CD80/CD86/HLA-DR markers.

Gutjahr A, et al. JCI Insight. 2019 Apr 4; 4(7): e125107.

diABZI STING agonist (Compound 3)

2',3'-cGAMP Sodium Salt and diABZI STING agonist demonstrate the most potent, broad-spectrum antiviral function.

Jr GG, et al. Cell Rep Med. 2023 May 16;4(5):101024.

2',3'-cGAMP Sodium Salt関連製品

関連化合物ライブラリー	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Bioactive Compound Library-Ⅱ	もっと見る

STING阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
PBMC	Function assay	69.6 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in CXCL10 mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis	31820985
PBMC	Function assay	1.39 to 139 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in IFNbeta release at 1.39 to 139 uM measured after 4 hrs by ELISA	31820985
PBMC	Function assay	69.6 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in IFNbeta mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis	31820985
PBMC	Function assay	69.6 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in IL6 mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis	31820985
PBMC	Function assay	139 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in IL6 production at 139 uM measured after 4 hrs by ELISA	31820985
293T	Function assay		30 mins	Activation of recombinant human STING haplotype R71H/G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.02 μM.	31715099
293T	Function assay		30 mins	Activation of recombinant human wild-type STING expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.02 μM.	31715099
293T	Function assay		30 mins	Activation of recombinant human STING haplotype G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.04 μM.	31715099
293T	Function assay		30 mins	Activation of recombinant human STING haplotype R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.05 μM.	31715099
293T	Function assay		30 mins	Activation of recombinant human STING haplotype R232H mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.07 μM.	31715099
293T	Function assay		7 hrs	Activation of recombinant human wild-type STING expressed in 293T cells incubated for 7 hrs in absence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 13.7 μM.	31715099
THP1	Function assay		20 hrs	Agonist activity at STING in human THP1 cells assessed as stimulation of IRF3 pathway measured after 20 hrs by luciferase reporter gene assay, EC50 = 38.6 μM.	31820985
B16-OVA	Antitumor assay			Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as tumour regression in injected flank at 10 ug administered intratumorally on day 6, 9 and 12 post implantation	31500996
B16-OVA	Antitumor assay			Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as tumour regression in contralateral flank at 10 ug administered intratumorally on day 6, 9 and 12 post implantation	31500996
B16-OVA	Antitumor assay			Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as higher number of mouse cured of tumors at 10 ug administered intratumorally on day 6, 9 and 12 post implantation	31500996
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Targets

STING ^[1]
(Cell-free assay)

3.79 nM(Kd)

In Vitro
In vitro	2',3'-cGAMP is an endogenous second messenger produced by mammalian cells. 2',3'-cGAMP is a high affinity ligand for STING. 2',3'-cGAMP is a potent inducer of type-I interferons. 2',3'-cGAMP binding induces conformational changes of STING.^[1]
細胞実験	細胞株	A549, BSC-40, BSR-T7, Vero cells
	濃度	25 μM, 20 μM, 2.5 μM
	反応時間	30 min
	実験の流れ	A549 cells are infected at an MOI of 5 with WT VACV or VACV-ΔPoxin and lysed 5 hpi. As a positive control, cells are permeabilized for 30 min with digitonin buffer (10 μg ml−1 digitonin, 50 mM HEPES-KOH pH 7.5, 100 mM KCl, 3 mM MgCl2, 0.1 mM DTT, 85 mM sucrose, 0.2% BSA, 1 mM ATP, and 0.1 mM GTP) and stimulated with or without 25 μM 2',3'-cGAMP. After stimulation, the cells are washed once with DMEM supplemented with 10% FBS, media is replaced, and cells are incubated 5 h before lysis.

参考
[1] Xu Zhang, et al. Mol Cell. 2013 Jul 25;51(2):226-35. [2] James B Eaglesham, et al. Nature. 2019 Feb;566(7743):259-263.

参考

化学情報

分子量	718.37	化学式	C₂₀H₂₂N₁₀Na₂O₁₃P₂
CAS No.	1441190-66-4 (free acid)	SDF	--
密度	g/mL
Smiles	C1C2C(C(C(O2)N3C=NC4=C3N=C(NC4=O)N)OP(=O)(OCC5C(C(C(O5)N6C=NC7=C(N=CN=C76)N)O)OP(=O)(O1)O)O)O
保管	3 years -20°C powder	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3 years -20°C powder	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 100 mg/mL ( (139.2 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : 100 mg/mL

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):